Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene

IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial patients in ChinaUnder strategic collaboration agreement...
May 30, 2024 09:21 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024

COLUMBUS, Ohio, May 30, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
April 29, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces ‘Menopause’ Journal Publication of Article on Oral Lasofoxifene’s Effects on Vaginal Atrophy in Postmenopausal Women

COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
April 19, 2024 16:26 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024

COLUMBUS, Ohio, April 19, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic...
February 12, 2024 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website

COLUMBUS, Ohio, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
January 10, 2024 19:30 ET | Source: Sermonix Pharmaceuticals Inc.

Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene

Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rightsHenlius to facilitate...
December 12, 2023 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life

Most patients minimized or hid side effects from their health care providers for fear of negative perceptions, reduced treatment efficacy, or being taken off a drug or out of a clinical trialSexual...
December 12, 2023 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations

COLUMBUS, Ohio, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
December 11, 2023 09:00 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology

COLUMBUS, Ohio, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
November 28, 2023 09:01 ET | Source: Sermonix Pharmaceuticals Inc.

Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium

COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right